| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -8.9 | -7.4 |
| EPS (diluted, $ a share) | $-0.26 | $-0.60 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: QTTB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Q32 Bio Inc.: key numbers
- Share price
- $8.29Close, Nov 16
- Market cap
- $248M
- Shares outstanding
- 29.92MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Q32 Bio Inc.
All →Q32 Bio Financial Results
Q32 Bio reported third quarter 2026 financial results and provided a corporate update, including clinical data from its SIGNAL-AA trial of bempikibart. The company ended the quarter with $289.6 million in cash, which is expected to fund operations through Phase 3 topline results. Management plans to initiate a registration-directed program for bempikibart in severe alopecia areata in the first half of 2027.
- Term
- Q3 2026
“The third quarter brought continued momentum for Q32 Bio and our bempikibart program. We shared encouraging SIGNAL-AA Part B results in late-breaking oral and poster presentations at EADV, highlighting bempikibart’s clinically meaningful efficacy data at Week 36 and ability to induce durable responses that were maintained or deepened through the 16-week off-drug period, supporting the potential for less frequent, chronic maintenance dosing”
Jodie Morrison, Chief Executive Officer of Q32 Bio
“We believe our data demonstrates the potential for bempikibart to become a first-line standard of care option for patients with alopecia areata. We are pleased to welcome José and Ellie to lead the advancement of bempikibart into late-stage development and have made key senior appointments spanning clinical operations, clinical strategy and medical affairs, and regulatory affairs.”
Jodie Morrison, Chief Executive Officer of Q32 Bio
Q32 Bio CEO Jodie Pope Morrison Sells $26.8K of Stock
Jodie Pope Morrison, CEO, sold 3,221 shares of Q32 Bio Inc. at $8.32 a share, worth $26.8K in total on Oct 6, 2026. Shares held after the trade: 340,038 (-0.9%).
- Value
- $26.8K
- Shares
- 3,221
- Price
- $8.32
- Role
- CEO
- Holding change
- -0.9%
- Trade date
- Oct 6, 2026
Q32 Bio CFO and President Lee Kalowski Sells $10.8K of Stock
Lee Kalowski, CFO and President, sold 1,301 shares of Q32 Bio Inc. at $8.32 a share, worth $10.8K in total on Oct 6, 2026. Shares held after the trade: 137,170 (-0.9%).
- Value
- $10.8K
- Shares
- 1,301
- Price
- $8.32
- Role
- CFO and President
- Holding change
- -0.9%
- Trade date
- Oct 6, 2026
Q32 Bio Clinical Trial Data
Q32 Bio presented additional 36-week results and initial 16-week off-drug findings from its SIGNAL-AA Phase 2a trial of bempikibart in patients with severe alopecia areata. The data showed clinically meaningful efficacy, including a 35.3% mean reduction in SALT scores, and supported the drug's advancement into a registration-directed program in the first half of 2027.
“Bempikibart’s robust efficacy data and durability observed across the 36-week treatment period and 16-week off-drug period in both JAK inhibitor-experienced and JAK inhibitor-naïve patients, changes on biomarkers supportive of its bifunctional mechanism, and its favorable safety and tolerability profile support its continued development in a registration-directed program in patients with severe or very severe alopecia areata as well as in expanded alopecia areata populations and other autoimmune and inflammatory indications.”
Jodie Morrison, Chief Executive Officer of Q32 Bio
Q32 Bio Leadership Change
Q32 Bio appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. Both executives bring extensive experience in late-stage clinical development and regulatory strategy as the company prepares to advance bempikibart into a registration-directed program for alopecia areata in 2027.